SSA
CTIC

Schonfeld Strategic Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,953,712
Closed -$8.21M – 2724
2023
Q1 		$8.21M Buy
1,953,712
+206,112
+12% +$1.07M 0.08% 334
2022
Q4 		$10.5M Buy
1,747,600
+418,124
+31% +$2.28M 0.09% 292
2022
Q3 		$7.74M Buy
1,329,476
+481,776
+57% +$3M 0.06% 389
2022
Q2 		$5.06M Buy
847,700
+638,100
+304% +$3.27M 0.05% 467
2022
Q1 		$978K Buy
209,600
+38,400
+22% +$115K 0.01% 1003
2021
Q4 		$424K Buy
171,200
+95,200
+125% +$233K ﹤0.01% 1346
2021
Q3 		$224K Sell
76,000
-1,000
-1% -$2.72K ﹤0.01% 1709
2021
Q2 		$193K Buy
77,000
+36,474
+90% +$87.5K ﹤0.01% 1689
2021
Q1 		$117K Sell
40,526
-4,574
-10% -$14.9K ﹤0.01% 1615
2020
Q4 		$145K Buy
+45,100
New +$150K ﹤0.01% 1398

Other funds holding CTIC

UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Schonfeld Strategic Advisors's CTIC Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,953,712 shares — an estimated $8.21M sold.

Schonfeld Strategic Advisors first reported a position in CTIC in Q4 2020 and held it in 10 quarters. The position peaked at $10.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • Schonfeld Strategic Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,953,712 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $8.21M.
  • Schonfeld Strategic Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $10.5M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.